Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Disorders of Hemostasis01:24

Disorders of Hemostasis

918
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
918
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

330
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
330
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enoxaparin, Tinzaparin, and Apixaban Modulate Cancer Cell Procoagulant Activity and Viability: Comparison with Quercetin.

Cancers·2026
Same author

'What' and 'How' to Measure in Allergy and Clinical Immunology: A Systematic Review of Core Outcome Sets and Outcome Harmonisation Processes.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Sex Differences in Cancer-Associated Thrombosis.

International journal of molecular sciences·2026
Same author

Structured exercise training and rehabilitation in patients with acute venous thromboembolism: a systematic review of randomized controlled trials.

European journal of preventive cardiology·2026
Same author

Catastrophic Antiphospholipid Syndrome.

Seminars in thrombosis and hemostasis·2026
Same author

Combined Oral Contraceptives and the Risk of Thrombosis.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jul 5, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

384

Catastrophic Antiphospholipid Syndrome.

Victoria Bitsadze1, Fidan Yakubova1, Jamilya Khizroeva1

  • 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children's Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str. 8-2, 119991 Moscow, Russia.

International Journal of Molecular Sciences
|January 11, 2024
PubMed
Summary
This summary is machine-generated.

Catastrophic Antiphospholipid Syndrome (CAPS) involves severe microthrombosis and inflammation. Prompt diagnosis and interdisciplinary care, including LMWH, are crucial for improving outcomes and reducing mortality in CAPS patients.

Keywords:
antiphospholipid antibodiesantiphospholipid syndromecatastrophic antiphospholipid syndromecomplications of pregnancy

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

568

Related Experiment Videos

Last Updated: Jul 5, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

384
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

568

Area of Science:

  • Immunology
  • Hematology
  • Rheumatology

Background:

  • Catastrophic Antiphospholipid Syndrome (CAPS) is a rare, life-threatening condition characterized by widespread microthrombosis.
  • Unlike classic Antiphospholipid Syndrome (APS), CAPS involves a severe inflammatory response termed a "thrombotic storm."
  • CAPS often presents following infection, trauma, or surgery, with symptoms including fever, thrombocytopenia, and multi-organ failure.

Purpose of the Study:

  • To highlight the diagnostic challenges in CAPS, particularly the fluctuating antiphospholipid antibody levels.
  • To outline current therapeutic strategies for managing CAPS.
  • To emphasize the need for improved clinical protocols and medical education for better patient outcomes.

Main Methods:

  • Review of clinical presentation and diagnostic criteria for CAPS.
  • Analysis of current treatment modalities, including triple therapy (anticoagulants, plasmapheresis, glucocorticosteroids) and LMWH.
  • Discussion of the multifactorial nature and management complexities of CAPS.

Main Results:

  • Antiphospholipid antibody levels can fluctuate, complicating CAPS diagnosis.
  • Triple therapy is a common treatment, with LMWH recommended for its anti-inflammatory and anticoagulant properties.
  • Effective management requires an interdisciplinary approach, timely diagnosis, and preventative strategies.

Conclusions:

  • CAPS necessitates specialized medical care and timely diagnosis to mitigate severe consequences.
  • Enhanced clinical protocols and education are vital for improving therapeutic approaches and reducing CAPS-related mortality.
  • Early recognition and management are key to addressing the "thrombotic storm" characteristic of CAPS.